<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496883</url>
  </required_header>
  <id_info>
    <org_study_id>UCincinnatifastest</org_study_id>
    <secondary_id>1U01NS110772-01</secondary_id>
    <secondary_id>2019-003722-25</secondary_id>
    <secondary_id>U1111-1201-0087</secondary_id>
    <nct_id>NCT03496883</nct_id>
  </id_info>
  <brief_title>Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial</brief_title>
  <acronym>FASTEST</acronym>
  <official_title>Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Broderick, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time&#xD;
      (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral&#xD;
      hemorrhage (ICH) within a time window and subgroup of patients that is most likely to&#xD;
      benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke&#xD;
      onset with an identified subgroup of patients most likely to benefit, will improve outcomes&#xD;
      at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as&#xD;
      compared to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a global, Phase III, randomized, double-blind controlled trial&#xD;
      of rFVIIa plus best standard therapy vs. placebo and best standard therapy alone. The&#xD;
      investigators will include participants with a volume of ICH ≥ 2 and &lt; 60 cc, no more than a&#xD;
      small volume of intraventricular hemorrhage (IVH) (IVH score ≤ 7), age ≥ 18 and ≤ 80, Glasgow&#xD;
      Coma Scale of ≥ 8, and treated within 120 minutes from stroke onset. To minimize&#xD;
      time-to-treatment, the study will use emergency research informed consent procedures&#xD;
      (including exception from informed consent (EFIC) in the United States) and mobile stroke&#xD;
      units (MSUs), with a goal of ½ of participants treated within 90 minutes, as accomplished in&#xD;
      the NINDS t-PA trials. The FASTEST Trial will include approximately 100 hospital sites and at&#xD;
      least 15 MSUs in the NINDS-funded StrokeNet and key global institutions with large volumes of&#xD;
      ICH patients and the ability to treat them within 120 minutes of stroke onset. Recruitment of&#xD;
      860 participants over 3½ years is planned. Countries participating in the trial include the&#xD;
      United States, Canada, Japan, Germany, Spain, and the United Kingdom.&#xD;
&#xD;
      Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum&#xD;
      10 mg dose) or placebo. Participants in both arms will receive best standard therapy as per&#xD;
      published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.&#xD;
      The primary outcome (ordinal mRS with the following categories: 0-2, 3, and 4-6) will be&#xD;
      determined at 180 days, but participants will be followed by remote assessment at 30 days and&#xD;
      90 days. To measure growth of ICH, all participants will have a standard of care baseline&#xD;
      non-contrast CT of the head and a repeat scan at 24 hours. Centralized volumetric&#xD;
      measurements of ICH, IVH, and edema will be performed for both time points.&#xD;
&#xD;
      Novo Nordisk A/S will manufacture and supply rFVIIa as a research medication for use in the&#xD;
      FASTEST Trial. Novo Nordisk A/S will also manufacture and supply matching placebo that is&#xD;
      identical to rFVIIa in appearance and administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded study medication</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>180 days</time_frame>
    <description>Ordinal distribution with the following steps: 0-2, 3, 4-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>180 days</time_frame>
    <description>Utility-weighted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>180 days</time_frame>
    <description>Score of 0-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>180 days</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the volume of ICH and ICH+IVH</measure>
    <time_frame>Between baseline CT and 24-hour CT</time_frame>
    <description>As measured by non-contrast CT of the head</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>90 days</time_frame>
    <description>Quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>180 days</time_frame>
    <description>Ordinal distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Recombinant Activated Factor VII (rFVIIa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Activated Factor VII (rFVIIa)</intervention_name>
    <description>Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.</description>
    <arm_group_label>Recombinant Activated Factor VII (rFVIIa)</arm_group_label>
    <other_name>NovoSeven</other_name>
    <other_name>NiaStase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-80 years, inclusive&#xD;
&#xD;
          2. Patients with spontaneous ICH&#xD;
&#xD;
          3. Able to treat with study medication (rFVIIa/placebo) within 120 minutes of stroke&#xD;
             onset or last known well&#xD;
&#xD;
          4. Efforts to obtain informed consent per EFIC guidelines (U.S.) or adherence to&#xD;
             country-specific emergency research informed consent regulations (Canada, Germany,&#xD;
             Spain, U.K., Japan)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Score of 3 to 7 on the Glasgow Coma Scale&#xD;
&#xD;
          2. Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous&#xD;
             malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral&#xD;
             anticoagulants) within the past 7 days, coagulopathy, etc.)&#xD;
&#xD;
          3. ICH volume &lt; 2 cc or ≥ 60 cc&#xD;
&#xD;
          4. IVH score &gt; 7&#xD;
&#xD;
          5. Pre-existing disability (mRS &gt; 2)&#xD;
&#xD;
          6. Symptomatic thrombotic or vaso-occlusive disease in past 90 days (e.g., cerebral&#xD;
             infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or&#xD;
             unstable angina)&#xD;
&#xD;
          7. Clinical or EKG evidence of ST elevation consistent with acute myocardial ischemia&#xD;
&#xD;
          8. Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)&#xD;
&#xD;
          9. Refusal to participate in study by patient, legal representative, or family member&#xD;
&#xD;
         10. Known or suspected thrombocytopenia (unless current platelet count documented above&#xD;
             50,000/μL)&#xD;
&#xD;
         11. Unfractionated heparin use with abnormal PTT&#xD;
&#xD;
         12. Low-molecular weight heparin use within the previous 24 hours&#xD;
&#xD;
         13. Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular&#xD;
             angioplasty or stenting&#xD;
&#xD;
         14. Advanced or terminal illness or any other condition the investigator feels would pose&#xD;
             a significant hazard to the patient if rFVIIa were administered&#xD;
&#xD;
         15. Recent (within 30 days) participation in any investigational drug or device trial or&#xD;
             earlier participation in any investigational drug or device trial for which the&#xD;
             duration of effect is expected to persist until to the time of FASTEST enrollment&#xD;
&#xD;
         16. Planned withdrawal of care or comfort care measures&#xD;
&#xD;
         17. Patient known or suspected of not being able to comply with trial protocol (e.g., due&#xD;
             to alcoholism, drug dependency, or psychological disorder)&#xD;
&#xD;
         18. Known or suspected allergy to trial medication(s), excipients, or related products&#xD;
&#xD;
         19. Contraindications to study medication&#xD;
&#xD;
         20. Previous participation in this trial (previously randomized)&#xD;
&#xD;
         21. Females of childbearing potential who are known to be pregnant or within 12 weeks&#xD;
             post-partum and/or lactating at time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Broderick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Broderick, MD</last_name>
    <phone>(513) 919-5404</phone>
    <email>joseph.broderick@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Grotta, MD</last_name>
    <phone>(281) 387-2329</phone>
    <email>james.c.grotta@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Health La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Meyer, MD</last_name>
      <email>bcmeyer@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center - Hillcrest Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Meyer, MD</last_name>
      <email>bcmeyer@health.ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Joseph Broderick, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results to be reported on ClinicalTrials.gov, and trial database prepared for NINDS for sharing with other investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Available 12 months after publication of primary results</ipd_time_frame>
    <ipd_access_criteria>Approval by NINDS</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

